Which types of epileptic seizures are vigabatrin/vigabatrin suitable for treating?
Vigabatrin/vigabatrin is a GABA transaminase inhibitor. By inhibiting the degradation of GABA, it significantly increases the concentration of γ-aminobutyric acid (GABA) in the brain, inhibiting nerve excitation conduction and controlling epileptic seizures. According to international mainstream guidelines and drug instructions, vigabatrin is mainly suitable for the following types of epileptic seizures:
First, the most common and most research-supported are infantile spasms.Infantile Spasms. This is a severe epilepsy syndrome of infancy with a unique seizure pattern, clinically characterized by myoclonus or flexor seizures. Vigabatrin is one of the first-choice drugs approved by the U.S. Food and Drug Administration (FDA) to treat this condition, especially when used in combination with corticosteroids.

Secondly, vigabatrin is also suitable for refractory partial-onset seizures (Refractory Partial-Onset Seizures), especially cases that are ineffective or poorly controlled by other anti-epileptic drugs. It has application value in both children and adults, especially as an adjuvant treatment, where it can serve as a complementary mechanism to enhance the overall efficacy of anti-epileptic drugs.
It should be noted that vigabatrin is not suitable for first-line treatment of generalized seizures (such as absence seizures or myoclonic seizures) because it has limited efficacy in these types and may even worsen symptoms. When choosing to use vigabatrin, comprehensive judgment should be made based on the type of epilepsy, electrophysiological manifestations, and neuroimaging evaluation to ensure maximum responsiveness and safety to the drug. In addition, because vigabatrin has the potential risk of serious adverse reactions such as visual field defects, its use is mostly based on weighing the pros and cons after a clear diagnosis, combined with vision monitoring and neurological follow-up.
Reference materials:https://www.sabril.net/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)